Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer

s to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 65,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Amrubicin. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results sum
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:3/31/2015)... N.C. , March 31, 2015 PGI ... capabilities in North America at ... facility. The anticipated plant expansion is centered ... a need for differentiated products for personal care product ... state-of-the-art printing capabilities with in-line slitting and packaging, will ...
(Date:3/31/2015)... Israel, March 31, 2015  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of ... liver diseases and cholesterol gallstones, today announced financial ... 2014. Fourth Quarter 2014 Highlights: ... a keynote address by Professor Rohit Loomba, MD, ...
(Date:3/31/2015)... , Mar. 27, 2015 Research and Markets ... addition of the "European Laboratory Information System ... by Type (Clinical Pathology Laboratory Information System, Anatomic ... report to their offering. The ... grow at a CAGR of 7.6% from 2014 ...
Breaking Medicine Technology:PGI Expands Manufacturing Capabilities At Mexico Plant 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 2European Laboratory Information System Market Report 2015: Germany holds a larger share of the laboratory information systems market 3
... Vista Partners announced today that it has updated coverage ... PRWP ) ("the Company") and maintains its twelve month target ... stated, "DAVANAT®, the Company,s lead product candidate, could potentially enhance ... Avastin® , while also reducing the side effect profile of ...
... Tenn. and MERCER ISLAND, Wash., Dec. 22, 2010 Renal ... to form the third largest provider of dialysis services in ...  The transaction – terms of which were not disclosed – ... 5,300 employees serving more than 19,000 patients in 260 locations ...
Cached Medicine Technology:Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10 2Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3
(Date:3/31/2015)... (PRWEB) March 31, 2015 St. Joseph ... growing network of leading healthcare systems, major physician groups ... information for the benefit of patients. The health information ... that supports well coordinated care throughout the continuum of ... a long tradition of providing services to a broad ...
(Date:3/31/2015)... Juvent Sports ( http://www.juventsports.com ) recently ... show in Orlando. At the show, former LPGA golf ... was interviewed and she shared the life-changing physical improvements ... began integrating the Juvent Pro Micro-Impact Platform™ into her ... instrumental to her chronic back pain recovery that it ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 An individual’s ... most important ligaments in the leg providing stability, load ... their study at today’s Specialty Day meeting of the ... utilized MRI data to determine the potential for biologic ... currently understood about the healing of meniscus tears when ...
(Date:3/31/2015)... Bend, Indiana (PRWEB) March 31, 2015 ... Lee DeRose in Youngstown, Ohio in 1987. ... of the curve with not just customer satisfaction, ... has been added to the well-stocked arsenal of ... manufactured by American Green Technology® (AGT). The patented ...
(Date:3/31/2015)... Wis. (PRWEB) March 31, 2015 For ... patients and a faster return on their investment, ... composition analyzer at Obesity Medicine 2015, April 8-12 at ... busy weight loss centers and medical offices, Rice Lake’s ... a health assessment tool. Obesity Medicine 2015 delivers clinical ...
Breaking Medicine News(10 mins):Health News:St. Joseph Medical Center Joins Other Leading Healthcare Systems Participating in Greater Houston Healthconnect 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 2Health News:Former LPGA Tour Winner Maggie Will Discovers The Juvent Micro-Impact Platform as a Pain Relief Breakthrough and Performance Enhancer 3Health News:New Way to Evaluate Meniscus Tear Outcomes 2Health News:American Green Technology® Signs Exclusive Agreement to Distribute Health Risk Management System in Midwest 2Health News:Rice Lake Weighing Systems’ Body Composition Analyzer On Display at Obesity Medicine 2015 2
... (HealthDay News) -- A possible new risk factor for death ... The study of almost 1,300 people aged 65 and ... smoothly the heart rate returns to normal after a premature ... follow-up, abnormal heart rate turbulence was associated with an eight ...
... News) -- Americans living in parts of Appalachia and ... in their free time, according to federal government estimates ... likely to be physically active during leisure time are ... rates are 29.2 percent or greater for more than ...
... of regulatory T cells in the tumors of breast cancer ... long been unclear. Now new research at the ... regulatory T cells, whose job is to help mediate the ... and intensify the spread of breast cancer to distant organs ...
... is available in German . , ... and Efficiency in Health Care (IQWiG) published the results ... on coronary heart disease (CHD). The aim of the ... of high methodological quality that may be relevant for ...
... Hospital (MGH) study has identified a new role for an ... metastases. Published in the early edition of Proceedings ... how focal adhesion kinase (FAK) is involved in producing areas ... part of the premetastatic process and increases expression of ...
... in clinical trials expect that their personal information will ... Khaled El-Emam, Canada Research Chair in Electronic Health Information ... practices used to transfer and share sensitive files were ... Are Passwords Used to Protect Personal Health Information in ...
Cached Medicine News:Health News:Appalachia, the South Home to Least-Active Americans: CDC 2Health News:Key culprit identified in breast cancer metastasis 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Enzyme helps prepare lung tissue for metastatic development 2Health News:Study reveals security weaknesses in file-sharing methods used in clinical trials 2
... Cards. Insert the card and turn on the ... off after the programmed time. The Smart Card ... Simply provide your patient with the appropriate card ... the next visit.,The initial set of programmes covers ...
... ELPHA 4 Conti is a battery operated dual-channel ... of conditions described below. ELPHA 4 Conti also ... STRESS- and faecal incontinence ELPHA 4 Conti provokes ... the user can feel which muscles need exercising. ...
... template is designed for single-use ... the need for cleaning. The ... silicone molded over a metal ... placement while maintaining needle support ...
... The Reusable Template is designed ... a guidance system for prostate brachytherapy. ... on your software match the graphics ... with two pins protruding from lower ...
Medicine Products: